Evidence map›Paper›PMID 36625832›Full record

ArticleHuman vaccines & immunotherapeutics2023

Progression of hemolysis in a patient with hereditary spherocytosis after the second dose of COVID-19 mRNA vaccine.

Jun Nomura, Masafumi Seki, Syori Abe, Tadahiro Kobayashi, Yoko Okitsu, Noriko Fukuhara, Shinichiro Takahashi, Hideo Harigae, Junichi Kameoka

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jun NomuraDepartment of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai-shi, Japan.
Masafumi SekiDepartment of Infectious Diseases and Infection Control, International Medical Center, Saitama Medical University School of Medicine, Saitama, Japan.
Syori AbeDepartment of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai-shi, Japan.
Tadahiro KobayashiDepartment of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai-shi, Japan.
Yoko OkitsuDepartment of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai-shi, Japan.
Noriko FukuharaDepartment of Hematology, Tohoku University, Sendai-shi, Japan.
Shinichiro TakahashiDepartment of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai-shi, Japan.
Hideo HarigaeDepartment of Hematology, Tohoku University, Sendai-shi, Japan.
Junichi KameokaDepartment of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai-shi, Japan.
Tohoku Medical and Pharmaceutical University · JPTohoku University · JPSaitama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Herein, we report the case of a 22-year-old woman with hereditary spherocytosis (HS) whose condition worsened after administration of the coronavirus disease 2019 (COVID-19), mRNA vaccine 'BNT162b2 Pfizer-BioNTech.' The woman had been diagnosed with HS in 2005, and her condition remained stable until February 2021. In March 2021, she received the first dose of the above vaccine and experienced pain at the injection site. After the second dose in April 2021, she developed fever and general malaise. Investigations revealed progression of hemolysis, which improved after a few days. To the best of our knowledge, this is the first report of progression of hemolysis in a patient with HS after administration of the mRNA vaccine COVID-19, BNT162b2 'Pfizer-BioNTech.'

Indexed as

COVID-19COVID-19 VaccinesAdultBNT162 VaccineFemaleHemolysisHumansmRNA VaccinesYoung AdultBNT162 VaccineCOVID-19 VaccinesmRNA VaccineshemolysisHereditary Spherocytosis (HS)inflammatory cytokinesmRNA vaccine BNT162b2 ‘Pfizer-BioNtech’second vaccination

Identifiers

PMID36625832
PMCPMC10012938
OpenAlexW4315435895

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.